Estriol_MS_17936_MedChemExpress
- 格式:pdf
- 大小:152.32 KB
- 文档页数:2


LC-MS/MS法测定人血浆中吡咯替尼的浓度及其临床应用作者:赵振寰荆伟丽刘涛吕志强曹志红徐文来源:《中国药房》2021年第22期中图分类号 R917 文献标志码 A 文章编号 1001-0408(2021)22-2767-05DOI 10.6039/j.issn.1001-0408.2021.22.14摘要目的:建立测定吡咯替尼血药浓度的方法,并应用于临床。
方法:血浆样本经甲醇沉淀蛋白后,以伊马替尼为内标,采用液相色谱-串联质谱(LC-MS/MS)法测定。
以Ultimate AQ-C18为色谱柱,以甲醇(含0.1%甲酸)-水(0.1%甲酸)为流动相进行梯度洗脱,流速为0.4 mL/min,柱温为40 ℃,进样量为5 µL。
离子源为电喷雾离子源,以多反应监测模式进行正离子扫描,用于定量分析的离子对分别为m/z 583.4→138.3(吡咯替尼)、494.5→393.4(内标)。
选择2020年6-11月于青岛大学附属医院接受吡咯替尼治疗的乳腺癌患者30例,测定其用药1周后的吡咯替尼稳态谷濃度。
结果:吡咯替尼检测质量浓度的线性范围为5~300ng/mL(r=0.999 3),定量下限为5 ng/mL;日内、日间RSD均不高于9.30%,相对误差为-6.70%~5.04%;稳定性试验的相对误差为 -1.92%~5.42%;提取方法、基质效应、残留效应均不影响待测物的定量分析。
30例乳腺癌患者体内吡咯替尼的稳态谷浓度为32.6~82.8 ng/mL,平均血药浓度为53.8 ng/mL,存在2.54倍的个体差异。
结论:所建LC-MS/MS法操作简便、灵敏度和准确度较高,可用于乳腺癌患者体内吡咯替尼的血药浓度监测。
关键词吡咯替尼;液相色谱-串联质谱法;伊马替尼;乳腺癌;血药浓度监测Determination of Pyrrotinib Concentration in Human Plasma by LC-MS/MS and Its Clinical ApplicationZHAO Zhenhuan,JING Weili,LIU Tao,LYU Zhiqiang,CAO Zhihong,XU Wen(Dept. of Pharmacy, the Affiliated Hospital of Qingdao University, Shandong Qingdao 266003,China)ABSTRACT OBJECTIVE: To establish a method for the determination of pyrrotinib concentration in plasma, and apply it in clinic. METHODS: After precipitated with methanol,the plasma sample was determined by LC-MS/MS using imatinib as internal standard. The determination was performed on Ultimate AQ-C18 column with mobile phase consisted of methanol (containing 0.1% formic acid) and water (containing 0.1% formic acid)(gradient elution) at the flow rate of 0.4 mL/min. The column temperature was 40 ℃, and the sample size was 5 µL. The ion source was electrospray ionization source, and the positive ion scanning was carried out in multiple rea ction mode. The ion pairs for quantitative analysis were m/z 583.4→138.3 (pyrrotinib)and m/z 494.5→393.4 (internal standard), respectively. Thirty breast cancer patients taking pyrrotinib were collected from the Affiliated Hospital of Qingdao University during Jun.-Nov. 2020 to determine their steady-state trough concentrations of pyrrotinib after a week of treatment. RESULTS: The linear range of pyrrotinib were 5-300 ng/mL (r=0.999 3). The lower limit of quantification was 5 ng/mL. RSDs of intra-day and inter-day were not higher than 9.30%, and relative errors (REs) ranged -6.70%-5.04%. REs of stability tests were in the range of -1.92%-5.42%. The extraction method, matrix effect and residual effect did not affect the quantitative analysis of the substance to be tested. The steady-state trough concentrations of pyrrotinib were 32.6-82.8 ng/mL,with an average plasma concentration of 53.8 ng/mL; there was about 2.54 fold individual difference. CONCLUSIONS: Established LC-MS/MS method is simple, sensitive and accurate, and can be used for the plasma concentration monitoring of pyrrotinib in breast cancer patient.KEYWORDS Pyrrotinib; LC-MS/MS; Imatinib; Breast cancer; Plasma concentration monitoring乳腺癌是威胁女性健康的常见恶性肿瘤之一,其发病率在女性恶性肿瘤患者中排第1位,病死率排第2位[1]。
第52卷第9期 辽 宁 化 工 Vol.52,No. 9 2023年9月 Liaoning Chemical Industry September,2023收稿日期: 2022-09-12HPLC 法测定阿瑞匹坦中基因毒性杂质3-氯甲基-1,2,4-三唑啉-5-酮常月赏,兰公剑*,王阔,陶蕾(南京正大天晴制药有限公司,江苏 南京 210046)摘 要:建立了液相色谱法测定阿瑞匹坦基因毒性杂质3-氯甲基-1,2,4-三唑啉-5-酮的分析方法。
采用安捷伦Poroshell 120系列EC -C18柱为色谱柱,0.1%磷酸溶液为流动相A,乙腈为流动相B,进行线性梯度洗脱,流速为1.0 mL ·min -1,柱温为30 ℃;检测波长为210 nm。
结果表明:溶剂空白及主峰不干扰该杂质的测定;该杂质在限度浓度20%~200%的范围内线性关系良好;该杂质的回收率在99.3%~101.0%范围内,RSD 小于5.0%;对照品溶液及供试液在室温放置18 h 内稳定;重复性和中间精密度RSD 均小于5.0%。
本方法专属性及精密度好,准确度高,可以用于本品中基因毒性杂质3-氯甲 基-1,2,4-三唑啉-5-酮的检测。
关 键 词:阿瑞匹坦;基因毒性杂质;3-氯甲基-1,2,4-三唑啉-5-酮;液相色谱法(HPLC) 中图分类号:TQ460.7 文献标识码: A 文章编号: 1004-0935(2023)09-1399-04阿瑞匹坦与其他止吐药物联合用药,适用于预防高度致吐性抗肿瘤化疗的初次和重复治疗过程中出现的急性和迟发性恶心和呕吐[1-6]。
阿瑞匹坦具有全新的药理作用机制,其作为首个神经激肽-1(NK -1)受体拮抗剂为预防和治疗癌症患者化疗引起的恶心呕吐提供了更多的药物治疗选择[7-9]。
3-氯甲基-1,2,4-三唑啉-5-酮是合成阿瑞匹坦的关键物料,属三唑啉酮类衍生物[10]。
3-氯甲基-1,2, 4-三唑啉-5-酮为单卤代烷烃化合物[11-12],依据ICH M7,该化合物具有基因警示结构。